Corvus Pharma Com (CRVS) |
|
4.02 0.34 (9.24%)
|
08-14 16:00 |
|
Open: |
3.76 |
Pre. Close: |
3.68 |
|
High:
|
4.194 |
Low:
|
3.6261 |
|
Volume:
|
390,172 |
Market Cap:
|
113M |
|
|
|
|
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.192 - 4.217 |
4.217 - 4.242 |
|
Low:
|
3.577 - 3.603 |
3.603 - 3.629 |
|
Close:
|
3.976 - 4.018 |
4.018 - 4.059 |
|
Technical analysis |
as of: 2020-08-14 4:28:44 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 5.31 One year: 6.06 |
| Support: |
Support1: 3.50 Support2: 2.91 |
| Resistance: |
Resistance1: 4.54 Resistance2: 5.19 |
| Pivot: |
4.11  |
| Moving Average: |
MA(5): 3.97 MA(20): 4.20
MA(100): 3.29 MA(250): 3.59 |
| MACD: |
MACD(12,26): 0.03 Signal(9): 0.11 |
| Stochastic oscillator: |
%K(14,3): 20.92 %D(3): 16.95 |
| RSI: |
RSI(14): 49.90 |
| 52-week: |
High: 6.88 Low: 1.01 Change(%): -4.3 |
| Average Vol(K): |
3-Month: 218121 10-Days: 30929 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.CRVS has closed above bottom band by 36.7%. Bollinger Bands are 47.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to CRVS's normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Wed, 12 Aug 2020
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) Becomes The New Buzzing Stock: Sports A Monthly Volatility Of 9.62% - The Comet Reports
Tue, 04 Aug 2020
Corvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference - Yahoo Finance
Mon, 03 Aug 2020
How Much Of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Do Insiders Own? - yahoo.com
Sun, 02 Aug 2020
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2020 Results - Earnings Call Transcript - Seeking Alpha
Thu, 30 Jul 2020
Corvus: 2Q Earnings Snapshot - San Francisco Chronicle
Wed, 29 Jul 2020
Corvus Pharmaceuticals Inc. (CRVS) Soars 6.12% on July 29 - Equities.com
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ Global Market |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
28 |
| Shares Float (M) |
14 |
|
% Held by Insiders
|
6.31 |
|
% Held by Institutions
|
75.64 |
|
Shares Short (K)
|
424 |
|
Shares Short P. Month (K)
|
328 |
Stock Financials |
|
EPS
|
-1.633 |
|
EPS Est This Year
|
-3.180 |
|
EPS Est Next Year
|
-3.410 |
|
Book Value (p.s.)
|
2.150 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-33.5 |
|
Return on Equity (ttm)
|
-59.7 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-1.756 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-38 |
|
Levered Free Cash Flow (M)
|
-20 |
Stock Valuations |
|
PE Ratio
|
-2.46 |
|
PEG Ratio
|
|
|
Price to Book value
|
1.87 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-2.98 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
